hg204
Gene therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2024 (NCT06615206)
Timeline
No events for the selected filters.
Mechanism of action
- Methyl-CpG-binding protein 2ANTISENSE INHIBITOR
MECP2 antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06615206 | N/A | Nov 1, 2024 | HuidaGene Therapeutics Co., Ltd., Peking University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| HuidaGene Therapeutics Co., Ltd. | For profit | 1 | 1 | 1 | 2024 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1